



Australian Government
Department of Health
Therapeutic Goods Administration

SERIOUS SHORTAGE SUBSTITUTION NOTICE

Notice Reference Number	SSSN 20-06
--------------------------------	------------

This Notice applies for the following dates

From	4/09/2020	To	31/12/2020
-------------	-----------	-----------	------------

This Notice applies only to the following medicines

Name of medicines in shortage (including strength and formulation):	Olmesartan (as olmesartan medoxomil) film coated tablets blister pack – multiple strengths
Schedule:	S4: Prescription Only Medicine
Duration of shortage:	Expected to be resolved between September and November 2020. For further and any updated information, see: http://apps.tga.gov.au/Prod/msi/Search/Details/olmesartan-medoxomil

Details of medicine to be supplied under this SSSN

Name of medicines (including strength and formulation) to be supplied	Olmesartan (as olmesartan medoxomil) film coated tablets blister pack – alternative strength
Same formulation but different strength?	Yes, see dosage substitution table below

Same active but different salt?	No
Different dose form?	No

Dosage substitution table

Original medicine dose	20 mg	40 mg
Alternative strength to be supplied as a substitute	40 mg	20 mg
	Ensure correct dose is provided – Follow dosage substitution regimen below	
Dosage substitution regimen	Calculate the number of tablets required to provide the prescribed dose noting that tablets may need to be cut in half. Dose interval remains unchanged.	
Any restrictions on this dose form (e.g. dose intervals)	N/A	
Any limitations on substitution	N/A	

Conditions:

- Total quantity supplied under this protocol must be equivalent to the number of days supplied on original prescription.
- The patient/carer must provide a valid prescription for the original medicine that is in shortage.
- The patient/carer must consent to receiving a substitute medicine supplied pursuant to the notice.
- The pharmacist may, in their professional judgement, determine that the patient is not suitable to receive alternative medicine under the notice e.g. known previous hypersensitivity or severe adverse reaction to excipients.